genetic predisposition neuroblastoma mediated lmo1 super-enhancer polymorphism
neuroblastoma paediatric malignancy typically arises early childhood derived developing sympathetic nervous system clinical phenotypes range localized tumours excellent outcomes widely metastatic disease long-term survival approximately % despite intensive therapy previous genome-wide association study identified common polymorphisms lmo1 gene locus highly associated neuroblastoma susceptibility oncogenic addiction lmo1 tumour cells investigate causal dna variant locus mechanism leads neuroblastoma tumorigenesis first imputed possible genotypes across lmo1 locus mapped highly associated single nucleotide polymorphism snps areas chromatin accessibility evolutionary conservation transcription factor binding sites show snp rs2168101 g>t highly associated variant combined p x - odds ratio % confidence interval - resides super-enhancer defined extensive acetylation histone h3 lysine within first intron lmo1 ancestral g allele associated tumour formation resides conserved gata transcription factor binding motif show newly evolved protective tata allele associated decreased total lmo1 expression p neuroblastoma primary tumours ablates gata3 binding p < demonstrate allelic imbalance favouring g-containing strand tumours heterozygous snp demonstrated rna sequencing p < reporter assays p findings indicate recently evolved polymorphism within super-enhancer element first intron lmo1 influences neuroblastoma susceptibility differential gata transcription factor binding direct modulation lmo1 expression cis leads oncogenic dependency tumour cells
